Ricevi le ultime notizie sulle azioni Protara Therapeutics con aggiornamenti su tendenze di mercato, dati finanziari e analisi di Benzinga. Rimani informato sulle performance di TARA

Ultime notizie per

Protara Therapeutics

Protara Therapeutics, Inc. - Common Stock

Protara Therapeutics Inc

Taraxa

Tarachi Gold Corp

TARANIS RESOURCES INC ORD by Taranis Resources Inc.

Taranis Resources Inc

Arcturus Therapeutics Holdings Inc. - Common Stock

Arcturus Therapeutics

CAMP4 Therapeutics Corporation - Common Stock

Camp4 Therapeutics

Perspective Therapeutics, Inc. Common Stock

Perspective Therapeutics

Crescent Biopharma

Compugen

Coherus Oncology

Corbus Pharmaceuticals Holdings, Inc. - Common Stock

Corbus Pharmaceuticals

Caribou Biosciences

Forte Biosciences

Fennec Pharmaceuticals Inc. - Common Stock

Fennec Pharmaceuticals

Genfit

Genelux

Heron Therapeutics

Humacyte

Insight Molecular Diagnostics Inc. - Common Stock

Insight Molecular

Innate Pharma S.A. - American Depositary Shares

Innate Pharma

Molecular Partners AG - American Depositary Shares

Molecular Partners

Protalix BioTherapeutics, Inc. (DE) Common Stock

Protalix BioTherapeutics

Cartesian Therapeutics, Inc. - Common Stock

Cartesian Therapeutics

SELLAS Life Sciences Group, Inc. - Common Stock

SELLAS Life Sciences Gr

Tiziana Life Sciences Ltd - Common Shares

Tiziana Life Sciences

TriSalus Life Sciences, Inc. - Common Stock

TriSalus Life Sciences

Tonix Pharmaceuticals Holding Corp. - Common Stock

Tonix Pharmaceuticals

Voyager Therapeutics, Inc. - Common Stock

Voyager Therapeutics

Exagen

Protara Therapeutics (TARA) Previsione

Notizie

Utili

Quote.Nav.option-chain

Valutazioni degli analisti

Insider trading

Vendite allo scoperto

Rapporto azionario

Protara Therapeutics Inc is committed to identifying and advancing transformative therapies for people with cancer and rare diseases. The company discovers, develops and delivers breakthrough therapies to people who have limited treatment options. Its portfolio includes its program, TARA-002, being developed for the treatment of lymphatic malformations, and intravenous (IV) choline chloride, a phospholipid substrate replacement therapy for the treatment of intestinal failure associated liver disease (IFALD).

Comments

Protara Therapeutics Notizie sulle azioni

Notizie

Ultime notizie per

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO